Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Jun 25

PMID 38916448

Authors

Sun M Lim

Seong-San Kang

Dong K Kim

Soo-Hwan Lee

Chun-Bong Synn

Sujeong Baek

Seung M Yang

Yu J Han

Mi H Kim

Heekyung Han

Kwangmin Na

Young T Kim

Mi R Yun

Jae H Kim

Youngseon Byeon

Young S Kim

Jii B Lee

Min H Hong

Joshua C Curtin

Bharvin Patel

Isabelle Bergiers

Kyoung-Ho Pyo

Byoung C Cho

Affiliations

Soon will be listed here.

Abstract

Significance: Amivantamab in synergy with pembrolizumab effectively eradicated EGFRHIGHMETHIGH tumor subcluster in the tumor microenvironment of head and neck squamous cell carcinoma and overcame resistance against anti-PD-1 immunotherapy.

Citing Articles

Future investigative directions for novel therapeutic targets in head and neck cancer.

Nguyen J, Woerner L, Johnson D, Grandis J Expert Rev Anticancer Ther. 2024; 24(11):1067-1084.

PMID: 39412140 PMC: 11514385. DOI: 10.1080/14737140.2024.2417038.

References

Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F . Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer. 2019; 120(5):527-536. PMC: 6461865. DOI: 10.1038/s41416-018-0315-3. View

Yun J, Lee S, Kim S, Jeong S, Kim J, Pyo K . Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020; 10(8):1194-1209. DOI: 10.1158/2159-8290.CD-20-0116. View

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-12. DOI: 10.1038/44385. View

Apostolova P, Pearce E . Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment. Trends Immunol. 2022; 43(12):969-977. PMC: 10905416. DOI: 10.1016/j.it.2022.10.005. View

Feng Q, Liu Z, Yu X, Huang T, Chen J, Wang J . Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat Commun. 2022; 13(1):4981. PMC: 9448806. DOI: 10.1038/s41467-022-32521-8. View

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

Aguiar Jr P, Santoro I, Tadokoro H, de Lima Lopes G, Filardi B, Oliveira P . The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016; 8(4):479-88. DOI: 10.2217/imt-2015-0002. View

Kalbasi A, Ribas A . Antigen Presentation Keeps Trending in Immunotherapy Resistance. Clin Cancer Res. 2018; 24(14):3239-3241. PMC: 6050090. DOI: 10.1158/1078-0432.CCR-18-0698. View

Sanmamed M, Berraondo P, Rodriguez-Ruiz M, Melero I . Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer. 2022; 3(6):665-680. DOI: 10.1038/s43018-022-00401-1. View

10.

Saigi M, Alburquerque-Bejar J, Leer-Florin A, Pereira C, Pros E, Romero O . -Oncogenic and -Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer. Clin Cancer Res. 2018; 24(18):4579-4587. DOI: 10.1158/1078-0432.CCR-18-0267. View

11.

Murciano-Goroff Y, Betof Warner A, Wolchok J . The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020; 30(6):507-519. PMC: 7264181. DOI: 10.1038/s41422-020-0337-2. View

12.

Klebanoff C, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones A, Finkelstein S . Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102(27):9571-6. PMC: 1172264. DOI: 10.1073/pnas.0503726102. View

13.

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

14.

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

15.

Rameshbabu S, Labadie B, Argulian A, Patnaik A . Targeting Innate Immunity in Cancer Therapy. Vaccines (Basel). 2021; 9(2). PMC: 7916062. DOI: 10.3390/vaccines9020138. View

16.

Bader J, Voss K, Rathmell J . Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020; 78(6):1019-1033. PMC: 7339967. DOI: 10.1016/j.molcel.2020.05.034. View

17.

Rehmani H, Issaeva N . EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations. Ann Transl Med. 2020; 8(13):813. PMC: 7396252. DOI: 10.21037/atm.2020.04.07. View

18.

Park K, Haura E, Leighl N, Mitchell P, Shu C, Girard N . Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021; 39(30):3391-3402. PMC: 8791812. DOI: 10.1200/JCO.21.00662. View

19.

Syn N, Teng M, Mok T, Soo R . De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017; 18(12):e731-e741. DOI: 10.1016/S1470-2045(17)30607-1. View

20.

Wang Q, Sun L, Zhang Y, Wang Z, Zhao Z, Wang Z . MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas. J Immunother Cancer. 2021; 9(10). PMC: 8527154. DOI: 10.1136/jitc-2021-002451. View